Atlas Trials

A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

Clinical trial NCT07615426 · RECRUITING

Trial details

NCT number
NCT07615426
Sponsor
Janssen Research & Development, LLC
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Schizophrenia
Start date
2026-03-02
Primary completion
2027-06-21
Enrollment
64

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.